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Abstract 
Liposomes have been coated with the pH responsive polymer, Eudragit S100, and the 
formulation’s potential for lower GI targeting following oral administration assessed. 
Cationic liposomes were coated with the anionic polymer through simple mixing. The 
evolution of a polymer coat was studied using zeta potential measurements and laser 
diffraction size analysis. Further evidence of an association between polymer and liposome 
was obtained using light and cryo electron microscopy. Drug release studies were carried out 
at pH 1.4, pH 6.3 and pH 7.8, representing the pH conditions of the stomach, small intestine 
and ileocaecal junction, respectively. 
The polymer significantly reduced liposomal drug release at pH 1.4 and pH 6.3 but drug 
release was equivalent to the uncoated control at pH 7.8, indicating that the formulation 
displayed appropriate pH responsive release characteristics. While the coating layer was not 
able to withstand the additional challenge of bile salts this reinforces the importance of 
evaluating these types of formulations in more complex media.   
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1.0 Introduction 
Liposomes have been widely explored as drug delivery vehicles for several decades, offering 
temporal control of drug release and/or site specific drug delivery for a wide range of drugs 
with different physiochemical properties. To date they have found clinical utility primarily 
for the treatment of severe systemic infections and cancer (Cattel et al., 2004), for which their 
parenteral delivery is necessary and appropriate. To further exploit the advantages associated 
with liposomes (e.g. their ability to interact with cells (Voskuhl and Ravoo, 2008), the 
relative ease in which they can be produced in a wide range of structural and compositional 
configurations (Lasic, 1998), their potential in gene transfection (Montier et al., 2008) and 
capacity to carry a vast array of chemical and biopharmaceutical drugs (Lasic, 1998) it is 
beneficial to explore formulations with potential for non-parenteral delivery.  Indeed, a 
formulation suitable for oral drug delivery (widely accepted as the most practical, efficient 
and cost effective route for drug administration) could broaden the portfolio of applications 
for liposomes and open up several new avenues for treatment. 
  
Of growing interest generally in the world of oral drug delivery is colon-targeted delivery for 
treatment of both local and systemic conditions. It is recognised that this region of the 
gastrointestinal (GI) tract offers advantages over the stomach and small intestine, e.g. milder 
pH, lower enzymatic activity, lower bile salt concentrations, longer residence time and slower 
turnover of the mucus layer. For biopharmaceutical delivery, it also appears to offer the 
benefit of allowing greater functioning of absorption enhancers, thus allowing reasonable 
bioavailability of drugs such as peptides which would normally be poorly absorbed from the 
GI tract (Haupt and Rubinstein, 2002; Sinha et al., 2007).  
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Several researchers have already recognised the potential of combining the advantages of 
liposomes and colonic drug delivery. Rubenstein’s group (Tirosh et al., 2009 and Jubeh et al., 
2004) have investigated liposomal adhesion to healthy and inflamed colonic mucosa in vitro. 
Their work lays important foundations for understanding how liposomes may interact with 
colonic tissue. D’Argenio et al. (2006) have considered liposomes as vehicles for delivery of 
carnitine for the reversal of colitis. Kesisoglou et al. (2005) used liposomes for encapsulating 
5-aminosalicylate and 6-mercaptupurine against inflammatory bowel disease. Although for 
colonic action, administration of the liposomes in all of these studies was either intraluminal 
or in vitro to excised tissue; delivery via oral administration was not considered.  
 
One study that has considered liposomes in the context of oral administration to the colon is 
that of Xing et al. (2003) who describe a multicomponent drug delivery vehicle comprising 
drug loaded liposomes within Eudragit-coated alginate beads. Although both in vitro and in 
vivo results were promising, drug release was controlled by the alginate and not the 
liposomes and it was not clear whether the liposomes were released to allow them to undergo 
the advantageous interactions with colonic mucosa that are described above. A further 
potential drawback of the formulation was the complexity of its preparation (particularly the 
multiple process steps), potentially limiting economically viable commercial manufacture.  
 
In the present study the emphasis is therefore on simplicity of preparation, with the liposomes 
retaining dominance as the drug delivery vehicle. Taking the lead from the successful 
development of commercially available tablet formulations for colonic drug delivery 
(Baumgart and Sandborn, 2007), the methacrylic acid copolymer Eudragit S100 ® has been 
used as the coating material. This polymer, with its anionic carboxylic acid side groups, has a 
solubility threshold of pH 7, remaining insoluble at lower pH values. On the journey through 
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the gastrointestinal tract, it is generally accepted that pH 7 is not normally reached until at 
least the distal small bowel/ileocaecal region; thus drug release from formulations coated 
with Eudragit S100 is likely to commence at the junction between the small intestine and 
colon, continuing into the colon.  
 
2.0 Materials and methods 
2.1 Materials 
Liposomal membrane components included egg phosphatidylcholine (EPC) (a gift from 
Lipoid, Ludwigshafen, Germany, minimum 98 % purity), cholesterol (CH) (Sigma Aldrich, 
Dorset, UK, and stearylamine (SA) (Sigma Aldrich). SA was incorporated to give the 
liposomes a positive charge, facilitating electrostatic interaction with the anionic polymer. 
Vitamin B12 (Sigma Aldrich) was chosen as a model drug due to its high solubility in all of 
the release media used (thus ensuring drug release would not be limited by solubility). 
Eudragit S100, the pH responsive polymer used for the coating of the liposomes, was a gift 
from Evonik (Essen, Germany). For the drug release studies 0.1 M hydrochloric acid (HCl), 
Hanks’ balanced salt solution (99.015 mol % water, 0.95 % Hanks’ balanced salt and 
0.035 % sodium bicarbonate adjusted to pH 6.3 using 0.1 M HCl) and phosphate buffered 
saline (PBS, increased to pH 7.8 using tribasic sodium phosphate) were used to simulate the 
pH conditions of the stomach (Sinha and Kumaria, 2003 and Ibekwe et al., 2006), small 
intestine (Ibekwe et al., 2006) and ileocaecal junction (Khan et al., 1999), respectively. All 
components for the release media were purchased from Sigma Aldrich (Dorset, UK). All 
other chemicals and solvents used were of an analytical grade and used as received.  
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2.2 Preparation of liposomes and their formulation with Eudragit S100 
Liposomes were prepared using EPC and CH in the molar ratio 1:1, with SA comprising 5% 
of the total lipid. This level of SA (5 mol%) was chosen after an initial screening study 
showed that it increased the zeta potential of liposomes at pH 7.4 from -12 mV (without SA) 
to +63 mV. Higher levels of SA were not found to significantly increase zeta potential. The 
conventional thin film hydration method (Bangham et al., 1965) was used to produce 
multilamellar vesicles (MLVs) for the study. Briefly, the lipids were dissolved in 5 ml 
chloroform in a 50 ml round bottom flask. The chloroform was then removed using a rotary 
evaporator, leaving a thin lipid film on the side of the flask which was then dried under 
nitrogen for 2 hours to remove trace chloroform. The film was then hydrated with an aqueous 
solution containing 10 mg/ml of vitamin B12 in PBS (pH 7.4). During hydration the flask was 
agitated using a vortex mixer. Excess drug was removed through three cycles of 
centrifugation and replacement of supernatant with PBS. The final pellet was then re-
suspended in 10 ml of PBS.  
 
To prepare the coated liposomes equal volumes of liposomal suspension and aqueous 
solution of Eudragit S100 of various concentrations (0.0125, 0.025, 0.05 and 0.1 % w/v in 
PBS) were combined and hand-shaken for 2 minutes. 
 
2.3 Characterisation of liposomes 
2.3.1 Zeta potential 
Changes in dispersion zeta potential as a function of Eudragit S100 concentration were 
determined through electrophoretic mobility measurements (Zetamaster, Malvern 
Instruments, UK) at pH conditions in which the polymer was insoluble. Briefly, 500 µl of the 
liposome/polymer suspensions (from section 2.2.) were diluted with 20 ml of distilled water 
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(pH<7) before introducing to the electrophoresis cell. Ten measurements were taken at 25˚C 
on three independent samples of each preparation. 
  
2.3.2 Light Microscopy 
Light microscopy was conducted using an Olympus BX50 light microscope interfaced with a 
Leica Q500IW computer, with images taken using Ph 3 (phase plate) under the phase contrast 
setting. A small drop of liposome sample was placed on a pre-cleaned microscope slide 
before covering with a cover slip. Images were taken at 1000× magnification. 
 
2.3.3. Cryo-electron microscopy (cryo-EM)  
Drops of liposomal samples were dispersed into sample wells. The sample holder was then 
quenched in liquid nitrogen under vacuum conditions. Fracturing of the samples was 
conducted within the preparation chamber through the use of a fine blade. Samples were 
fractured using a Polaron Polar Preparation 2000 attached to a Phillips XL 30 Environmental 
Scanning Electron Microscope (ESEM). The samples were then coated with gold to increase 
conductivity and transferred into the SEM chamber. Images were taken at a maximum 
voltage of 3.0 kV to reduce temperature fluctuations associated with higher voltages, with the 
instrument maintained at -180°C by the periodic addition of liquid nitrogen to the cooling 
chamber.  
 
2.3.3 Size distribution 
Vesicle size and size distribution, as a function of Eudragit S100 concentration, were 
measured using wet laser diffraction particle sizing (Mastersizer 2000 connected to a Hydro 
SM small volume sample dispersion unit, Malvern Instruments, UK). Measurements were 
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carried out in distilled water in which the polymer was not soluble. Three independent 
formulations of each preparation were each measured 5 times.  
 
2.4 Drug release studies 
Drug release studies with uncoated liposomes and liposomes + polymer were conducted in 
each of the different pH media described in section 2.1. For each release experiment, 1 ml of 
liposomal suspension was added to 40 ml of preheated (37˚C) release medium and well-
agitated in an incubator maintained at 37°C. Sink conditions were maintained throughout 
each experiment. Aliquots of 1ml were removed at 0, 0.5, 1, 2, 4, 6, 10, 20, 30, 45, 70 and 
120 hours and centrifuged to precipitate the liposomes. The concentration of released vitamin 
B12 in the supernatant was determined using UV spectrophotometry against a standard curve 
obtained at λ=361 nm. All measurements were taken against reference samples of the 
appropriate dissolution medium. For each formulation, the initial amount of drug (mg drug/ 
mg phospholipid) prior to release was determined by lysing the liposomes with ethanol and 
measuring the resulting drug concentration using UV spectroscopy, allowing drug release to 
be reported as a percentage of the total encapsulated.  
 
Further drug release trials with uncoated and coated liposomes were completed in the 
presence of bile salts at a concentration representative of that found in the small intestine 
(10 mM sodium taurocholate in pH 6.3 Hanks’ solution). These trials aimed to test the 
liposomal formulations beyond response to pH alone. Over a period of 4 hours 
(representative of small intestine transit time) samples were removed and analysed 
spectrophotometrically at λ=361nm against a reference sample of the release medium.      
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3.0 Results 
 
The results presented in this section are discussed in section 4.  
 
Table 1 shows the vesicle zeta potential as a function of polymer concentration, where the 
polymer concentration shown is that of original solution that was mixed with the liposomes.  
As no further decrease in zeta potential was seen by increasing the polymer concentration 
beyond 0.05 % this was assumed to be the concentration necessary to cover the surface of the 
liposomes and was that used in all further studies. Vesicle size (Table 1) was seen to increase 
with increasing polymer concentration until 0.05 % at which point there was a plateau similar 
to that seen for the zeta potential results. 
 
Evidence of an association between the polymer and liposomes was also seen using light 
microscopy. Figure 1A shows the uncoated liposomes at pH 6.3. Typically for MLVs, the 
size of the vesicles was originally around 5 - 10 µm. On addition of polymer to a system at 
pH 7.8 no increase in size was observed (Figure 1B), consistent with the fact that the polymer 
was in solution at these conditions. At pH 6.3 the polymer was seen to precipitate around the 
vesicles forming larger agglomerates (Figure 1C). A control experiment (results not shown) 
in which liposomes were excluded showed that polymer ‘particles’ resulting from 
precipitation at pH 6.3 were considerably smaller (approximately 200 nm) than the liposomes 
used in this study. In this way, the agglomerates seen in Figure 1C were assumed to be 
liposomes + polymer and not precipitated polymer alone.  
 
In Figure 2 typical images from cryo-EM are shown. In Figure 2A the lamellae and central 
aqueous core of liposomes are clearly visible. In the presence of polymer a crust was 
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observed around and across the liposomes and the lamellae were no longer visible 
(Figure 2B).  
In Figure 3 drug release profiles for liposomes with and without polymer are shown in the 
different release media. At pH 1.4 and 6.3 (Figures 4A and B) the amount of drug released 
was significantly lower at all time points on addition of polymer (Mann Whitney U Test 
(chosen level of significance α=0.05). For example at pH 1.4, over a 20 hour period, only 
10 % of the drug was released, which is in contrast to the 40 % release over the same time 
period for the uncoated formulation. Over a time period more representative of gastric 
residence time (boxed graph in Figure 4A) only 2.5 % was released from the coated 
formulation compared to 10 % for the uncoated. However it can clearly be seen that although 
drug release was significantly reduced it was not abolished.  
 
Addition of bile salts to the release media significantly increased the drug release rate for 
both uncoated and coated liposomes. Interestingly there was no statistically significant 
difference between coated and uncoated formulations in the presence of bile salts indicating 
that both the structural integrity of the vesicles and the polymer barrier were affected by the 
bile salts.  
 
4.0 Discussion 
The formulation of liposomes into a preparation suitable for colon-targeted oral drug delivery 
could open up a range of new applications and indications extending the utility of liposomes. 
However, production and quality control of liposomal preparations can be difficult, hence the 
need to keep additional process steps and production methods as simple possible. Here we 
have therefore evaluated a conceptually simple idea of bringing together cationic liposomes 
and anionic polymer with the intention of creating a pH responsive coat around the liposomes 
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which would protect the vesicles en route through the stomach and the small intestine. This 
general route to coating has been previously explored when anionic liposomes were coated 
with the cationic polymer chitosan (Guo et al., 2003; Takeuchi et al., 1996, 2005), but no 
similar work has been completed using a pH responsive polymer for coating. The polymer 
Eudragit S100 was chosen as the coating material as it is widely used in both commercially 
available and experimental formulations for colonic targeting e.g. tablets (Khan et al., 1999 
and 2000), microspheres (Paharia et al., 2007) and capsules (Kraeling and Ritschel, 1992).    
 
The use of pH responsive materials for targeted oral delivery is not a perfect science and is 
not without its drawbacks. For example, substantial inter-patient differences in pH can lead to 
unpredictable targeting and release (Ibekwe et al., 2008). In the case of Eudragit S100, the 
likelihood of inappropriately early release upstream of the colon can also be increased when 
partial neutralisation of the polymer’s acidic function groups is carried out to facilitate 
creation of an ‘aqueous dispersion’ for coating purposes (Ibekwe et al., 2006b). Hence 
although the coating method explored here was one involving only aqueous solutions, 
unmodified Eudragit S100, albeit at low concentration, has been used to reduce the risk of 
drug release in the small intestine.  
 
Zeta potential measurements were used to monitor the evolution of the coat. This strategy has 
previously been used in the development of polymer-coated cationic and anionic liposomal 
formulations, where the point at which the zeta potential plateaus is taken to indicate 
saturation of the vesicle surface with polymer (Guo et al., 2003; Davidsen et al., 2001; 
Takeuchi et al., 2005). Results from our other studies (sizing, cryo-EM and drug release) 
indicate that such an assumption should be made with caution or that certainly further 
experimentation should always be carried out to provide information on the physical 
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characteristics and functionality of the coat. In Table 1, the plateau of the size increase 
beyond 0.05% indicates that the coat was not building up evenly – instead perhaps 
developing preferentially on some vesicles before others.  Light microscopy images in 
Figure 1 point to a heterogeneous distribution of polymer and in Figure 2 a discontinuous 
‘crust’ around the liposomes rather than a homogenous coat is observed. 
  
Despite these observations, the polymer was able to substantially slow down drug release at 
pH 1.4 and 6.3, presumably acting as a diffusional barrier.  However, it was unable to protect 
against bile salts which indicates that premature drug release and liposomal degradation could 
be expected in vivo. This is an interesting finding as it reinforces the importance of going 
beyond evaluation of liposomal formulations for site specific delivery in the GI tract on the 
basis of pH shifts alone. The addition of bile salts, while adopted by some researchers in 
examining in vitro liposomal release for oral delivery (e.g. Lee et al., 2005) has not been 
pursued by others (e.g. Guo et al., 2003; Filipović-Grčić et al., 2001). 
 
Drug release results in Figure 4 indicated that both the liposomes and the coat were disrupted 
by the bile salts.  It was hypothesised that damage to the coat could be due to either the bile 
salts interacting directly with the polymer, facilitating its dispersion, or a secondary effect of 
liposomal degradation i.e. once the liposomes were ‘digested’ the coat dispersed due to the 
lack of a vesicle core holding it in place. To explore which of these was more likely, we 
carried out an additional experiment in which Eudragit S100 powder (as received from the 
manufacturer) was dispersed in either Hanks’ solution or Hanks’ solution + sodium 
taurocholate and analysed using wet laser diffraction particle sizing over 2 hours. All material 
concentrations were equivalent to those of the drug release studies. The resulting polymer 
particle size distributions were identical in both dispersion media, indicating that the bile salts 
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did not facilitate polymer dispersion or dissolution. Additionally, infra red spectra of aqueous 
pastes containing polymer, bile salt and their mixture were recorded using a Fourier 
transform infra red (FT-IR) spectrometer (FT-IR-6300, Jasco, Great Dunmow, UK) with an 
attenuated total reflection (ATR) infrared optical unit (golden gate
TM
, part number 10586, 
Specac Ltd., Orpington, UK). The purpose of this analysis was to test for the presence of any 
chemical interaction between the paste components. Any interactions between the Eudragit 
and the bile salt would result in a shift in the peak positions (e.g. ester vibrations at 1150 cm
-1
 
and 1250 cm
-1
, and C=O vibrations of the carboxylic acid groups at 1705 cm
-1
)  associated 
with the functional groups involved in the interaction.  Examination of the spectra revealed 
no variation in peak position; in fact, the spectra could be superimposed. It therefore seems 
likely that disruption to the coat was due to the loss of liposome structure. While liposomes 
can be designed to increase their resistance to bile salts (Andrieux et al., 2009), it would also 
be necessary to improve the integrity of the coat to prevent bile salt ingress and strategies for 
encapsulating liposomes within microparticles are therefore being explored.  
5.0 Conclusion 
Eudragit S100 can be associated with cationic liposomes through a simple mixing strategy 
creating a barrier that significantly reduces liposomal drug release at pH conditions 
representative of the stomach and small intestine. The importance of evaluating coated 
liposomes for oral drug delivery beyond pH shift studies has been demonstrated with the 
addition of bile salts.  
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Table 1. The effect of Eudragit S100 addition upon the particle size (d50), size distribution 
(span*) and zeta potential of liposomes. Each value represents the overall mean of three 
independent experiments ± the standard error of the mean. *Span =    
 
 
Concentration of 
polymer coating 
solution (%w/v) d(50) (µm) Span Zeta potential (mV) 
0 7.7 ± 0.1 1.2 ± 0.1 63 ± 2.4 
0.01 13.1 ± 2.1 2.3 ± 0.2 45 ± 2.4 
0.025 22.0 ± 2.8 1.9 ± 0.4 28 ± 1.9 
0.05 22.0 ± 3.4 2.4 ± 0.3 -28 ± 1.3 
0.1 20.0 ± 1.7 2.0 ± 0.2 -30 ± 0.5 
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Figure captions 
 
Figure 1.  Light microscopy images showing liposomes: (A) without polymer, and in the 
presence of Eudragit S100 at (B) pH 7.8 and (C) pH 6.3. 
 
Figure 2. Cryo-SEM images of (A) uncoated liposomes in pH 6.3 and (B) liposomes in the 
presence of Eudragit S100.  
 
Figure 3. Drug release profiles for liposome formulations with (■) and without (◊) Eudragit 
S100 at (A) pH 1.4, (B) pH 6.3 and (C) pH 7.8. In Figure 4 (A) drug release over 2 hours is 
additionally highlighted, corresponding to the typical residence time in the stomach. Each 
data point represents the overall mean of three independent experiments ± the standard error 
of the mean. 
 
Figure 4. Drug release profiles for liposome formulations with (●) and without (▲) Eudragit 
S100 at pH 6.3 in the presence of 10mM sodium taurocholate. Release data from Figure 4 (B) 
(no bile salts) are shown for comparison with (■) and without (◊) Eudragit S100. Each value 
represents the overall mean of three independent experiments ± the standard error of the 
mean. 
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Figure 4.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
